Engineered Extracellular Vesicles in Treatment of Type 1 Diabetes Mellitus: A Prospective Review
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Raghav, Alok | - |
dc.contributor.author | Ashraf, Hamid | - |
dc.contributor.author | Jeong, Goo Bo | - |
dc.date.accessioned | 2022-12-06T00:40:04Z | - |
dc.date.available | 2022-12-06T00:40:04Z | - |
dc.date.created | 2022-12-06 | - |
dc.date.issued | 2022-12 | - |
dc.identifier.issn | 2227-9059 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/86209 | - |
dc.description.abstract | Insulin replacement is an available treatment for autoimmune type 1 diabetes mellitus (T1DM). There are multiple limitations in the treatment of autoimmune diseases such as T1DM by immunosuppression using drugs and chemicals. The advent of extracellular vesicle (EV)-based therapies for the treatment of various diseases has attracted much attention to the field of bio-nanomedicine. Tolerogenic nanoparticles can induce immune tolerance, especially in autoimmune diseases. EVs can deliver cargo to specific cells without restrictions. Accordingly, EVs can be used to deliver tolerogenic nanoparticles, including iron oxide-peptide-major histocompatibility complex, polyethylene glycol-silver-2-(1′H-indole-3′-carbonyl)-thiazole-4-carboxylic acid methyl ester, and carboxylated poly (lactic-co-glycolic acid) nanoparticles coupled with or encapsulating an antigen, to effectively treat autoimmune T1DM. The present work highlights the advances in exosome-based delivery of tolerogenic nanoparticles for the treatment of autoimmune T1DM. © 2022 by the authors. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | MDPI | - |
dc.relation.isPartOf | Biomedicines | - |
dc.title | Engineered Extracellular Vesicles in Treatment of Type 1 Diabetes Mellitus: A Prospective Review | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000900495000001 | - |
dc.identifier.doi | 10.3390/biomedicines10123042 | - |
dc.identifier.bibliographicCitation | Biomedicines, v.10, no.12 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.scopusid | 2-s2.0-85144694452 | - |
dc.citation.title | Biomedicines | - |
dc.citation.volume | 10 | - |
dc.citation.number | 12 | - |
dc.contributor.affiliatedAuthor | Jeong, Goo Bo | - |
dc.type.docType | Review | - |
dc.subject.keywordAuthor | extracellular vesicles | - |
dc.subject.keywordAuthor | immunosuppression | - |
dc.subject.keywordAuthor | insulin | - |
dc.subject.keywordAuthor | tolerogenic nanoparticles | - |
dc.subject.keywordAuthor | type 1 diabetes | - |
dc.subject.keywordPlus | T-CELLS | - |
dc.subject.keywordPlus | DENDRITIC CELLS | - |
dc.subject.keywordPlus | DELIVERY VEHICLES | - |
dc.subject.keywordPlus | IMMUNE-RESPONSES | - |
dc.subject.keywordPlus | HUMAN THYMUS | - |
dc.subject.keywordPlus | EXOSOMES | - |
dc.subject.keywordPlus | ANTIGEN | - |
dc.subject.keywordPlus | INSULIN | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.